Article
Tom Caravela
The most difficult parts of being an MSL and how to overcome them
Summary
In this episode, Tom Caravela speaks with Jonathan Horvath about his career journey and insights from the Rutgers fellowship program. Jonathan discusses the complexities and challenges of the MSL role, including organization, territory management, and building relationships with key opinion leaders (KOLs). He addresses internal pressures, performance metrics, and shares strategies for effective time and travel management to combat MSL burnout. The conversation explores navigating different KOL personalities and preparing for meetings. Jonathan also reflects on adapting to COVID-19 and future interactions, offering final advice for aspiring and current MSLs.
My guest today is Jonathan Horvath, former Director of Field Medical Affairs at Dova Pharmaceuticals and we discuss the most difficult parts of being an MSL and how to overcome them.
In this episode we discuss:
- Jonathan’s background
- One of the most challenging parts of being an MSL in his perspective
- KOL access
- The internal pressures and how to overcome
- Other challenges and difficulties that MSLs should be aware of to try to stay on top
- His advice on “MSL frustrations”
- Advice for MSLs moving into 2021 hopefully coming out of COVID pandemic for them to perform well and get through the challenges
- One piece of advice for MSLs to help them find success
MSL career, KOL relationships, MSL challenges, time management strategies, overcoming MSL burnout
Related Topics
You May Also Like
Tom Caravela
Podcast
MSL Talk: Tom Caravela
Over-Negotiation-How to Botch a Job Offer
Podcast
MSL Talk: Tom Caravela, Sarah Snyder
The Ideal Roadmap for New MSLs
Article
Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
Article
Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
Article
Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS